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Abstract
Complex diseases such as polycystic ovary syndrome (PCOS) are associated
with intricate pathophysiological, hormonal, and metabolic feedbacks that
make their early diagnosis challenging, thus increasing the prevalence risks for
obesity, cardiovascular, and fatty liver diseases. To explore the crosstalk
between endocrine and lipid metabolic pathways, we administered 3-iodothyr-
onamine (T1AM), a natural analog of thyroid hormone, in a mouse model of
PCOS and analyzed plasma and tissue extracts using multidisciplinary omics
and biochemical approaches. T1AM administration induces a profound tissue-
specific antilipogenic effect in liver and muscle by lowering gene expression of
key regulators of lipid metabolism, PTP1B and PLIN2, significantly increasing
metabolites (glucogenic, amino acids, carnitine, and citrate) levels, while
enhancing protection against oxidative stress. In contrast, T1AM has an
opposing effect on the regulation of estrogenic pathways in the ovary by
upregulating STAR, CYP11A1, and CYP17A1. Biochemical measurements pro-
vide further evidence of significant reduction in liver cholesterol and triglyc-
erides in post-T1AM treatment. Our results shed light onto tissue-specific
metabolic vs. hormonal pathway interactions, thus illuminating the intricacies
within the pathophysiology of PCOS. This study opens up new avenues to
design drugs for targeted therapeutics to improve quality of life in complex
metabolic diseases.
Introduction
Polycystic ovary syndrome (PCOS) is a complex disease
with endocrine and metabolic disorders. PCOS affects 10–
20% of women in reproductive age with serious health
outcomes such as infertility (Knochenhauer et al. 1998;
Diamanti-Kandarakis et al. 1999, 2004), obesity, type 2
diabetes, hyperandrogenism, and dyslipidemia (Cascella
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et al. 2008; Giallauria et al. 2008; Vinaixa et al. 2011).
PCOS etiology is still unknown. However, environmental,
(epi)genetic, and hormonal influences are thought to be
important in the development of PCOS (Coles et al.
2013). Recently, we showed that PCOS women exhibit
significantly diminished lipid oxidation, and perturbed
glucose and amino acid metabolism (Whigham et al.
2014).
To understand the metabolic changes in PCOS, we
developed a PCOS mouse model based on the method
of Chapman et al. (2009) (Haviland et al. 2012). In this
mouse model, we used prenatal glucocorticoid (GC)
exposure that resulted in metabolic dysfunctions in adult
females (Haviland et al. 2013). While GC treatment had
milder inhibitory effects on the reproductive system, it
still presented hallmarks of metabolic dysfunction in the
adult female offspring consistent with those observed in
women with PCOS (Haviland et al. 2012; Selen et al.
2015). Nuclear magnetic resonance (NMR)-based meta-
bolomics combined with breath 13CO2/
12CO2 stable iso-
tope fractionation analysis of GC-mice showed a
significant increase in fluxes through major pathways
(pentose phosphate (PP) and tricarboxylic acid (TCA)
energy metabolism), pointing to a higher NADPH level
(Haviland et al. 2012) that leads to increased lipid syn-
thesis. We hypothesized that preprogramming of the
metabolic dysfunction in the female offspring results
from increased fatty acids and cholesterol as precursors
for steroid hormone synthesis. To test this hypothesis,
we used 3-iodothyronamine (T1AM) as anti-hyperlipi-
demic agent.
T1AM is an endogenous compound structurally similar
to the thyroid (T4) hormone but with distinct functional
properties (Ghelardoni et al. 2014). A single dose of
T1AM has opposing physiological effects (e.g., reduction
in heart rate, metabolic rate, and body temperature) com-
pared with thyroid hormone (Chiellini et al. 2007; Scan-
lan 2011). Previously, in an obese mouse model, we
showed that single or chronic treatment with low-dose
T1AM (10 mg/kg/day) reduced body weight by 10–14%
while maintaining glucose homeostasis (Braulke et al.
2008; Haviland et al. 2013). Furthermore, T1AM treat-
ment resulted in increased lipid utilization without affect-
ing food consumption (Haviland et al. 2013), making it a
great candidate for treating metabolic dysfunction in GC-
mice that exhibited simultaneous increased lipogenesis
and decreased lipid oxidation. In this study, we examined
systemic changes and the tissue-specific effects of sub-
chronic T1AM treatment in the perturbed metabolic
pathways and their associated gene signaling that affects
lipid, cholesterol, and steroidogenic (hormonal) pathways
in the GC-mouse model.
Materials and Methods
Reagents
6-Beta-hydroxycortisol (Sigma-Aldrich Corp., St Louis,
MO), purified crystalline T1AM, was prepared as previ-
ously described (Scanlan et al. 2004). A vehicle solution
was made using dimethyl sulfoxide (DMSO) and 0.9%
medical grade saline (Hospira Corp. Lake Forest, IL).
Animal study
All animal procedures and methods were carried out in
accordance with the approved guidelines from University of
Wisconsin, College of Letters and Sciences, Animal Care
and Use Committee (Madison, WI protocol # L00408). We
used outbred CD-1 (n = 11) breeding pairs of mice from
Harlan (Indianapolis, IN). All CD-1 mice were acclimated
for 1 week prior to mating and after a vaginal plug con-
firmed mating (gestational day, GD, 1). To generate PCOS
mice, dams were assigned subcutaneous injections on GD
16 through GD 19 as previously described (Haviland et al.
2012). After weaning (~9 weeks), prenatally glucocorticoid-
treated F1 generation mice (GC-mice) were fed AIN-93G
diet (17.7% protein, 60.1% carbohydrate, and 7.2% fat)
(Haviland et al. 2012) until they reached about 50 g body
weight at approximately 28 weeks of age. The adult female
GC-mice were then randomly chosen from different litters
and assigned to two groups (n = 4): (1) Control GC-mice
(referred to as “GC”) were injected with the vehicle solution
composed of certified organic sesame oil as a fat soluble liq-
uid to minimize the amount of dimethyl sulfoxide (50 lL),
and (2) GC-mice were treated with 25 mg/kg/day T1AM in
the vehicle solution (GC+T1AM). Animals were fasted for
4 h each day prior to receiving T1AM treatment for a total
of 5 days. Blood was collected on day -4 (before the treat-
ment), and post-treatment at day 5. At the end of the treat-
ment period (day 5), mice were euthanized followed by
immediate blood withdrawal and removal of tissues (skele-
tal muscle, liver, ovary, and subcutaneous adipose). Plasma
was separated by heparinized tubes (Haviland et al. 2012;
Selen et al. 2015). All tissues were stored at80°C until fur-
ther analysis.
Sample preparation
Plasma
Plasma samples were processed for NMR experiments as
previously described (Haviland et al. 2012). The samples
were then reconstituted in plasma NMR buffer (i.e.,
20 mmol/L phosphate buffer containing 1 mmol/L
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formate, 0.5 mmol/L 4,4-dimethyl 4-silapentane-1-sulfo-
nic acid (DSS), and 0.1 mmol/L sodium fluoride (NaF))
and adjusted to pH 7.4  0.05.
Tissues
About 50 mg of frozen tissue samples was homogenized in
10 mmol/L phosphate buffer (Selen et al. 2015). The dried
supernatant was reconstituted in the tissue NMR buffer
(i.e., D2O (99.9% 2H), containing 1 mmol/L formate,
0.5 mmol/L DSS, and 0.1 mmol/L NaF) and pH=
7.4  0.05.
Data Collection and Analysis
Metabolomics study
All 1D 1H-NMR spectra were collected at 25°C on a 600-
MHz Varian VNMRS spectrometer as previously described
(Haviland et al. 2012; Selen et al. 2015). 1D 1H-NMR spec-
tra were referenced to DSS (internal reference) and their
concentrations were quantified relative to formate
(1 mmol/L) by Chenomx software version 6 (http://www.
chenomx.com). All data were log2-transformed prior to
analysis. Changes in the plasma and tissue metabolome of
the T1AM treatment GC (GC+T1AM) and GC groups
were evaluated using a partial least square discriminant
analysis (PLSDA) (Lindgren et al. 1996; Pattini et al.
2008; Teng 2013) (www.metaboanalyst.com). In PLSDA,
the variable on the projection (VIP) analysis shows
metabolites ranked according to their influence on group
separation (Eriksson et al. 2006). A subset of metabolites
with higher VIP values in Table S1 were denoted with the
letter “a” in Figure 2. Statistical significance was deter-
mined by Student’s t-test. A *P < 0.05 was set to signifi-
cant and **P < 0.1 was considered moderately significant,
where n = 4. Data are presented as mean  standard
error measurement (SEM). Heatmaps were generated
based on the fold differences (FD) between GC+T1AM
and GC groups as defined in equation 1 using R statistical
software program (http://www.R-project.org). FD is
defined by subtraction of a given metabolite concentration
in the GC group, [metabolite]GC, from the corresponding
metabolite concentration in the T1AM treatment group,
[metabolite] GC+T1AM.
FD ¼ ½MetaboliteGCþT1AM  ½MetaboliteGC (1)
Gene expression study
A total of 51 genes were profiled in four tissues (liver,
skeletal muscle, adipose, and ovary) by real-time RT-PCR
as previously described (Selen et al. 2015). Primers were
designed in-house using Beacon Designer Software v.7.9
(Premier Biosoft International, Palo Alto, CA) with a
junction primer strategy (Table S2). Tissue samples were
kept in RNALater-ICE prior to processing. Total RNA
was isolated with RNeasy Lipid Tissue Mini kit (Qiagen
GmbH, Hilden, GER). Tissues (50–100 mg) were homog-
enized in QiaZol buffer (Qiagen) with TissueRuptor (Qia-
gen) for 30–40 s. RNA integrity, concentration, and
purity were evaluated using Experion (Bio-Rad Laborato-
ries, Hercules, CA), and Cytation (Cytation 3, Winooski,
VT), respectively. RNA was retrotranscribed using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA). Relative quantification of gene transcripts was quan-
tified using SYBR Green using RT-PCR (Bio-Rad Labora-
tories, Hercules, CA). For data normalization, reference
genes from a list of tested genes (ACTB, RPLL13A, B2M,
GUSB, HPRT, KDM2B, PPIA, PSMD4, and TBP) were
chosen for muscle, ovary, and adipose tissues. Choice of
reference genes was based on testing expression stability
of nine candidate reference genes. RPL13A was selected as
the best suitable reference gene to normalize liver RT-
PCR products under our experimental condition. All reac-
tions were run in duplicate. Data were log2-transformed
prior to final analysis by the 2-DDCt method, as described
by Livak and Schmittgen (2001). Statistical significance
was determined by Student’s t-test. A P < 0.05 was set to
significant and denoted with “*”. Data are presented as
mean standard error measurement (SEM).
Biochemical Analysis
Triglyceride (TG), cholesterol, and hepatic protein
measurements
Liver samples were prepared for total triglyceride detec-
tion and quantification according to the manufacturer’s
manual (BioVision, Milpitas, CA). Liver total cholesterol
(TC) was measured using colorimetric kit (Wako Diag-
nostics, Richmond, VA). Frozen liver samples (~10–
20 mg) were homogenized in RIPA buffer (ab156034,
Abcam, Cambridge, MA) that contained a protease
inhibitor cocktail tablet (Roche Diagnosis, Mannheim,
GR), and protein concentrations were quantified by
Bradford assay (#500-0205, Bio-Rad Laboratories, Her-
cules, CA).
Plasma insulin, leptin, and adiponektin
measurements
Plasma samples were prepared at the time of sacrifice
as previously described (Haviland et al. 2012). Plasma
insulin and leptin levels were measured using mouse
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2017 | Vol. 5 | Iss. 1 | e13097
Page 3
E. S. Selen Alpergin et al. T1AM Untangles Endocrine–Metabolic Pathways in PCOS
ELISA kits (Crystal Chem, Downers Grove, IL).
Adiponektin level was measured by adiponectin EIA kit
(ACRP30, Norcross, GA).
Results
T1AM treatment results in weight loss and
significant decreases in triglyceride and
cholesterol levels
We administrated GC-mice with T1AM (25 mg
Kg1 day1) for 5 days to examine the effect of the
drug on body weight regulation and lipid profiles. The
T1AM treatment decreased body weight in GC-mice by
14% compared with the untreated corresponding group
(Table 1). In addition, T1AM reduced hepatic triglyc-
eride (TG) and cholesterol (TC) levels (Table 1), with-
out changing total hepatic protein level. Plasma glucose
concentrations in GC-mice are higher than in normal
obese mice (data not shown). After T1AM treatment,
glucose level was improved although it did not reach
the level in normal obese mice.
We examined the effect of T1AM on hormones regu-
lating glucose and lipids. Trends for decreased insulin
levels mirrors lowered glucose level in GC-mice. Plasma
adiponectin level showed a decreasing trend while
plasma leptin level increased in the T1AM treatment
group (Table 1).
Metabolome profiles of plasma, liver, and
muscle in T1AM-treated GC-mice show
normalization of major perturbed metabolic
pathways
Metabolic profiling of plasma, muscle, and liver tissues
using 1H-NMR analysis identified 60 metabolites that
belong to major pathways (Fig. 1A). PLSDA analysis of
plasma, liver, and muscle metabolome profiles shows clear
separations between GC+T1AM-treated and GC groups in
each respective tissue (Fig. 1B–D, and Table S1) indicating
marked effects of T1AM treatment, which mirrors the bio-
chemical phenotype associated with weight loss (Table 1).
To visualize the magnitude of change in the metabolome,
we applied fold difference (FD, equation 1 in Methods) to
the metabolites in each tissue with outputs shown in heat-
map representations (Fig. 2A–C). Our results show that
while some metabolic changes are common among all tis-
sues such as in liver, muscle, and plasma, there are a num-
ber of tissue-specific metabolic changes in the GC+T1AM-
treated group compared with the GC group.
Plasma
Decreased citrate and amino acids levels were previously
observed in women with PCOS (Atiomo and Daykin
2012; Zhao et al. 2012; Whigham et al. 2014). We com-
pared fold differences of metabolites in plasma of
GC+T1AM-treated and control GC-mice with metabolites
(P < 0.1) that are altered (Fig. 2A). These metabolites
including major increases in TCA cycle intermediates
citrate (Cit) and fumarate (Fum), amino acids and inter-
mediates (2-aminobutyrate (2-AB), alanine (Ala), betaine
(Bet), glutamine (Gln), isoleucine (Ile), leucine (Leu),
lysine (Lys), phenylalanine (Phe), proline (Pro), valine
(Val)), in addition to an important fatty acid carrier, car-
nitine (Carn), a sugar nucleotide metabolism intermedi-
ate, myo-inositol (myo-I) were all increased after T1AM
treatment (Fig. 2D). Direction of changes particularly in
amino acids and citrate levels indicates “normalization”
as the major metabolic effect of T1AM on altered path-
ways is consistent with previously found biomarkers in
women with PCOS.
Liver
Consistent with plasma data, T1AM treatment altered
hepatic amino acid metabolism pathway intermediates (2-
hydroxybutyrate (2-HB), 2-oxoisocaproate (2-OIC), phe,
and gly). Levels of glutathione, the substrate in a major
nonenzymatic antioxidant pathway, increased significantly
indicating a greater redox level due to T1AM treatment
(Fig. 2C).
Table 1. Biochemical parameters and body weight before and
after 5 days of T1AM (25 mg/kg) administration.
Measurements (units) Group Mean  SEM
Blood Glucose (mg/dL) GC 198.46  10.51
GC+T1AM 172.73  26.01
Liver Total Triglyceride (mg/dL) GC 2.294  0.06
GC+T1AM 1.268  0.006*
Liver Total Cholesterol (mg/dL) GC 50.98  1.036
GC+T1AM 34.00  4.106*
Hepatic Protein Content GC 76.73  0.61
GC+T1AM 77.25  0.24
Blood Insulin (ng/mL) GC 0.11  0.02
GC+T1AM 0.18  0.02
Plasma Adiponectin (lg/mL) GC 76.40  41.72
GC+T1AM 47.10  41.19
Plasma Leptin (ng/mL) GC 19.94  2.65
GC+T1AM 21.24  3.19
Body weight (gr) GC 49.425  2.81
GC+T1AM 42.450  3.16
SEM, standard error measurement.
Data are shown as standard mean values  SEM.
*Shows statistical significance level by student-test (P < 0.05 (n = 3)).
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Muscle
Metabolites that have important influences on the group
separation of metabolome profiles are shown in Figure 2C
and F. Levels of amino acid metabolic intermediates, glucose
oxidation intermediates, lipid metabolism intermediates
(acetate), PP pathway intermediate (UDP-glucose, UDP-
G), and a nonenzymatic antioxidant metabolism intermedi-
ate ascorbate (Asc) were increased, while glycerol (glyc), cit,
and glycine (gly) were all decreased after the treatment.
Tissue-specific targeted gene transcription
analysis by RT-PCR
To correlate changes in metabolic profiles, we examined
changes in gene transcription for targeted metabolic path-
ways in carbohydrate metabolism, fatty acid synthesis, cata-
bolism and transport, glucose, and steroidogenic pathways
in several tissues (Table S2). Figure 3A–D shows a heatmap
of fold difference in gene expression levels in liver, skeletal
muscle, adipose, and ovary tissues after GC+T1AM treat-
ment compared with the GC group. After T1AM adminis-
tration, most genes in lipid and carbohydrate metabolism
were all downregulated consistent with metabolic profiles
with the exception of steroidogenic pathways.
T1AM treatment shows differential tissue-
specific effects on lipid and cholesterol
metabolic pathways
The T1AM treatment had tissue-specific effects on fatty
acid metabolism and signaling pathways in the GC-mouse
model. In particular, T1AM had general effects on major
metabolic pathways (lipid, carbohydrate, and amino acid)
in muscle and adipose tissues, whereas in liver, it mainly
decreased gene transcription levels in lipid and cholesterol
metabolism (Fig. 3A–D).
Liver
Four major hepatic genes were downregulated by T1AM
treatment. These key genes are as follows: (1) protein tyr-
osine phosphatase 1B (PTP1B) that plays a major role in
the intersection of insulin and lipid regulatory signaling
pathways, (2) perilipin 2 (PLIN2) that regulates storage
and hydrolysis of neutral lipids, (3) acyl-CoA synthetase
long-chain family member 5 (ACSL5) that has a key role
in FA activation, and (4) 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR) that is a key enzyme in the initial
step of cholesterol synthesis (Fig. 4A).
Additional hepatic genes showed only decreasing
trends. These are ACC1, in de novo lipogenesis (DNL);
FAS, in FA synthase; glycerol-3-phosphate acyltransferase
(GPAM), monoacylglycerol transferase (MGAT), and dia-
cylglycerol transferase (DGAT), in triglycerides (TG) syn-
thesis; and regulator (SREBP2), in cholesterogenesis
(Fig. 3A).
Further support for the harmonic effect of T1AM treat-
ment on acute hepatic lipid metabolism pathways comes
from attenuation in expression levels of several regulatory
genes (PPAR-a, sirtuins (SIRT3, SIRT5, and SIRT6)) for
FA catabolism and their target pathways (malonyl-CoA
decarboxylase (MLYCD), acyl-CoA oxidase 1 palmitoyl
(ACOX1), 3-hydroxy-3-methylglutaryl-CoA synthase 2
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(HMGCS2), and the mitochondrial FA transporter (car-
nitine palmitoyltransferase 1a and carnitine O-acetyltrans-
ferase (CPT1A and CRAT)) (Fig. 3A, Table S2).
Skeletal muscle
Muscle lipid metabolism (utilization and synthesis) and
the regulatory gene transcription levels (Fig. 3A and
Fig. 4B) were distinct from liver. The concerted increased
levels of three key genes were as follows: FABP3, a gene
that encodes a protein for long-chain FA transport and
oxidation; PPAR-c, peroxisome proliferator-activated
receptor gamma that is a transcriptional regulator of lipo-
genic genes; and SIRT4 with an important regulatory role
in beta-oxidation in lipid metabolism. On the other hand,
T1AM also resulted in harmonic downregulation of
ACSL5, and SIRT6 consistent with the notion of increased
oxidation of long-chain FAs and possibly their turnover
in the muscle.
A number of genes associated with FA synthesis
(ACC1, ACC2, ACSL3, CD36) and FA oxidation (CPT1b
and BDH1 (Table S2) showed decreasing levels, which are
consistent with observed major changes in lipid metabolic
pathways through T1AM treatment (Figs. 3B and 4C).
Interestingly, a metabolic regulator (SIRT5), and tumor
suppressor p53 (P53, an important mediator of metabolic
and mitogenic pathways) were reduced after the treat-
ment with T1AM.
Adipose
T1AM induced specific changes in expression of six genes
that regulate lipid metabolism in white adipose tissue
(Fig. 4B). The ME1 gene decreased by ~ threefold, which
encodes malate dehydrogenase enzyme with antioxidant
metabolic activity and produces NADPH for lipid synthe-
sis. The expression level of adipogenic regulatory gene,
PPAR-c, was also reduced in the T1AM treatment group.
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Figure 4. Changes in transcription levels in major metabolic pathways in T1AM-treated GC-mice. Panels A–G show lipids, carbohydrates,
amino acids, and antioxidant pathways in liver, adipose, muscle, and ovary, respectively. In all graphs, black bars represent treatment and white
bars represent control groups, x-axis: gene IDs, and y-axis: gene expression levels relative to RPL13A by RT-PCR. * P < 0.1. Data are shown as
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gene or metabolite levels. BCAA: branch chain amino acid; BCKA, branch chain keto acid; TCA, citric acid cycle; BCAT2, branch chain
acetyltransferase 2; BCKDHa and BCKDHb, branch chain keto acid dehydrogenase subunits a and b.
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Expression levels of the positive transcriptional regulator
of genes involved in lipid catabolism (PPAR-a) and one
of its targets, MYLCAD, which catalyzes the production
of acetyl-CoA from malonyl-CoA, were downregulated in
treated GC-mice (Fig. 4B). On the other hand, the
decreased gene expression level of SIRT6, a long-chain
fatty acid binding protein, suggests increased lipolysis and
release of fatty acids from the adipose tissue.
ACSL5 and APOD (encodes apolipoprotein) transcrip-
tion levels in the T1AM-treated group showed increasing
trends in fold change analysis (Fig. 3C), which are consis-
tent with the overall observed effect of T1AM on
increased lipid catabolism and decreased lipogenesis in
adipose tissue.
Ovary
To understand the effect of T1AM on the cholesterol meta-
bolism in the reproductive tissue, we examined expression
levels of several genes in steroidogenic pathways in ovary.
Remarkably, T1AM treatment significantly increased
expression of key genes in steroid and cholesterol metabo-
lism (Fig. 3D) in this tissue. T1AM-treated mice elevated
STAR transcript that encodes for steroidogenic acute regu-
latory protein and coordinates cholesterol uptake and its
movement into mitochondria, CYP11a (also known as
P450SCC) gene that encodes for cholesterol side chain
cleavage enzyme and catalyzes the rate-limiting step of
steroidogenesis (i.e., the conversion of cholesterol to preg-
nenolone (Miller 1988)), and CYP17A1 that encodes ster-
oid 17-alpha-monooxygenase enzyme and participates in
androgen synthesis (Fig. 4D). These changes indicate that
response to T1AM in the ovary of GC-mice is different and
more likely due to its major pathophysiology as compared
to other metabolic tissues.
T1AM alters the biomarkers associated with
glucose metabolism pathways
Previous data suggested that glucose metabolism was
changed in both nondiabetic GC-mice and women with
PCOS. To further examine effect of T1AM on regulating
glucose metabolism in GC-mice, we measured transcrip-
tional levels of key signaling (PTP1B), regulatory
(GLUT2), transport (IRS2), and storage (GYS1) genes in
glucose metabolism. Our gene expression data indicate
that T1AM significantly changes expression of a few key
genes in carbohydrate metabolism in liver, muscle, and
adipose tissues.
In the liver, expression of PTP1B that encodes a pro-
tein in the insulin signaling pathway was reduced by
T1AM treatment, suggesting a normalization of glucose
metabolism in hepatic tissue of GC-mice (Fig. 4A). In
muscle tissue, IRS2 gene expression was significantly
upregulated in the T1AM treatment group (Fig. 4E). In
adipose tissue, GLUT2 that encodes glucose transporter 2
protein was increased, whereas the GYS1 gene that
encodes glycogen synthase enzyme (in the rate-limiting
step in glycogen synthesis) was downregulated in T1AM-
treated GC-mice (Fig. 4E), suggesting a shift from glucose
to lipid metabolism. Changes in gene expression in mus-
cle mirror those changes seen in metabolome profiles that
show increasing level of branched amino acids and
decreased level of glycine pointing to increased insulin
sensitivity in T1AM treatment.
T1AM treatment alters gene expression
levels of the branched chain amino acids in
muscle
To confirm observed changes in metabolic profiles of
branched chain amino acids (BCAA) in skeletal muscles,
we analyzed transcription levels of genes associated with
transamination and catabolism of BCAA metabolism.
Our results indicate that these genes were significantly
altered by T1AM treatment in muscle. The gene for
branched chain amino acid transaminase 2 (BCAT2)
that degrades BCAAs into branched chain keto acids
(BCKA) decreased, whereas expression of branched
chain keto acid dehydrogenase beta subunit (BCKDHB)
gene level increased in T1AM-treated GC-mice (Fig. 4F
and H). Coincidently, an important metabolic regulator
of ammonia detoxification and disposal (SIRT5) expres-
sion level was significantly downregulated in the T1AM-
treated group (Fig. 4F).
T1AM treatment increases antioxidant
pathways in muscle and liver
The metabolic profiling showed increased level of antioxi-
dant in tissues after T1AM treatment. We examined a
number of genes in oxidative stress pathways. P53 gene
expression level is generally lower in healthy cells. How-
ever, oxidative stress (Olovnikov et al. 2009) and acti-
vated oncogenes (Harris and Levine 2005) are known to
induce expression levels of the P53 gene. In muscle, P53
transcription level was reduced after T1AM administra-
tion in the GC-mice (Fig. 4G, P < 0.1). Furthermore, the
gene expression level of ME1 was upregulated in muscles
from the treatment group compared with GC-mice
(Fig. 4G). Increased gene levels in antioxidant metabolism
are consistent with an observed increased level of ascor-
bate (Fig. 2F) in muscle.
In liver, P53 expression level also showed a decreasing
trend in the T1AM treatment group (Fig. 3A), consistent
with the observed increased level of glutathione (Fig. 2E).
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Discussion
Increased lipogenesis, TG, and cholesterol levels have been
associated with complex metabolic disorders in women
with PCOS (Whigham et al. 2013) and in animal models
(e.g., rhesus monkey (Abbott et al. 2009) and prenatally
treated GC-mice (Haviland et al. 2012) leading to abnor-
malities and associated risk factors in developing lipotoxi-
city (Lelliott and Vidal-Puig 2004), fatty liver, type 2
diabetes (T2D), infertility (Moran et al. 2015), and car-
diovascular diseases (CVD)(Group, 2004; Diamanti-Kan-
darakis et al. 2007).
The GC mouse is a suitable corresponding model for
metabolic impairments in PCOS (Haviland et al. 2012).
Previously, we showed 5 days of treatment with low-dose
T1AM was optimum for weight reduction in normal
obese mice without affecting muscle breakdown (Havi-
land et al. 2013). Our main aim in this study was to
examine whether T1AM treatment could normalize meta-
bolic dysfunction in GC-mice and verify those metabolic
changes by targeted gene transcription and biochemical
assays.
The NMR metabolomics data show that subchronic treat-
ment with a pharmacological dose (25 mg kg1 day1)
of T1AM induces multiple effects in GC-mice that normal-
ize energy metabolism, increase lipid and antioxidant
metabolic pathways in a tissue-specific manner. Figure 5
shows schematics of changes in metabolic and gene
pathways in each tissue. Complementary targeted gene
transcriptome profiles show specifically that T1AM down-
regulates lipid and cholesterol synthetic pathways in liver
and muscle. Unlike changes seen in metabolically active
tissues, liver and muscle, steroidogenic pathways are upreg-
ulated in ovary of GC-mice pointing to the origin of
dysregulation of these pathways. Although T1AM results in
overlapping changes in regulatory and/or signaling genes in
different tissues, the metabolic lipid metabolism pathways
in liver are distinct from adipose and muscle, suggesting
that T1AM may have a multitargeted cellular-specific
mechanism of action that need to be examined further.
In liver, T1AM specifically affects the cholesterol path-
way and lipid storage and breakdown. Changes in hepatic
metabolic lipid pathways are mapped to downregulation
of two key genes, PTP1B and PLIN2 that play important
roles in regulating lipogenesis, that is, TG storage and
lipolysis (Fig. 5). Two other genes, ACSL5 and HMGCR,
at the crossroad between FA activation and the rate-limit-
ing step in cholesterogenesis, are also downregulated. In
addition, decreasing trends in other lipogenic genes in TG
synthesis and DNL support overall observed improve-
ments in the hepatic lipid and cholesterol profiles.
Increased levels of PPAR-c have been shown to regulate
lipid metabolism by increasing fat storage and synthesis
(Janani and Ranjitha Kumari 2015) in adipose tissue.
Treatment with T1AM protects against lipogenesis in GC-
mice through significant downregulation of PPAR-c along
with upregulation of SIRT6 transcription in adipose tissue
(Figs. 4B and 5A). Increased expression level of SIRT6
inhibits lipogenic transcription factors SREBP1 and
SREBP2 that regulate glycolysis and fatty acid metabo-
lism, while it mediates cholesterol homeostasis by lower-
ing LDL cholesterol under normal and HFD conditions
(Kanfi et al. 2010). In addition, SIRT6 is shown to bind
to long-chain FAs (Feldman et al. 2013). Our data show
an increase in SIRT6 transcription level (Fig. 4B) that fur-
ther supports downregulation of DNL and cholesterogen-
esis possibly through increased release of long-chain FAs
from adipocytes and their clearance in muscles as a major
energy source for FA oxidation by a reduction in ACSL
level in muscle and liver (Fig. 4A and 4C).
We previously showed that a chronic treatment with
the lowest pharmacological dose of T1AM (10 mg/kg) in
normal obese mice induces lipid oxidation (Haviland
et al. 2013) in addition to weight loss. Here, we show
increased FA utilization in muscles through upregulation
of FABP3 (Figs. 4A and 5A). FABP3 has been shown to
increase in response to FA exposure in vitro and in vivo
studies (Veerkamp and van Moerkerk 1993; Zanotti
1999). The fabp family of proteins functions in transport-
ing long-chain FAs to different cellular compartments, for
example, mitochondria and peroxisomes for FA oxidation
(Atshaves et al. 2010). In addition, acetylcarnitine is sig-
nificantly increased in T1AM-treated muscles from GC
mice. Acetyl-carnitine plays key roles during FA transport
and the initial step of FA oxidation in mitochondria
(Fritz and Mc 1959; Bremer 1962; McGarry and Brown
1997). Furthermore, the increased carnitine level in
plasma supports a higher demand for fatty acid oxidation
through the carnitine-mediated pathway to match the
increased lipid utilization level (Figs. 2D and 5A).
In muscle, both SIRT6 and P53 gene expression levels
(Fig. 4C and G) are significantly decreased consistent with
reduction of the citrate metabolite in the TCA cycle
(Fig. 2F), leading to a “normalized” energy balance and a
less oxidative environment. SIRT6 protein suppresses sev-
eral genes through histone modifications, including glu-
cokinase, pyruvate kinase, FA synthase, and acetyl-CoA
carboxylase (Kanfi et al. 2010). This is consistent with the
current observations that suggest an alternative epigenetic
regulatory mechanism by T1AM which requires further
examination.
T1AM has an additional metabolic correction by
increasing protective antioxidant defense mechanisms in
key highly metabolic tissues (Fig. 5). Previously, we
showed increased oxidative stress in kidneys from GC-
mice compared with normal mice under similar diets
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(Selen et al. 2015). In PCOS women, inefficient neutral-
ization of ROS is reported to increase oxidative stress
(Gonzalez et al. 2006; Victor et al. 2009) independent of
their weight, age, or metabolic abnormalities. Glutathione
and ascorbate are nonenzymatic antioxidant molecules
that trap and neutralize ROS reactions at the expense of
NADPH, as an essential cellular redox and buffering agent
(Bendich et al. 1986; Meister 1992; Mari et al. 2009).
Depletion of glutathione is shown during excess mito-
chondrial cholesterol loading in a mouse model (Mari
et al. 2006), while reduction in ascorbate level is associ-
ated with pathological accumulation of cholesterol and
TG in liver and other tissues (Nambisan and Kurup 1975;
Holloway and Rivers 1981). In addition, a Ascorbic acid
acts like an antioxidant that protects against lipid peroxi-
dation (Choi et al. 2016), or functions as an indirect
antioxidant, providing electrons to generate reactive forms
of other antioxidants such as glutathione (Bourges et al.
2005). Taken together, increased levels of glutathione in
liver and ascorbic acid in muscle indicate that the oxida-
tive environment in the tissues are reduced despite
increased lipid oxidation. T1AM also downregulates P53
in liver while upregulating ME1 in muscle, which are
accompanied with increased levels of ascorbate, glu-
tathione, and UDP-glucose. These pathways could gener-
ate NADPH as another potential antioxidant molecule
that is shared in intersecting pathways between lipogenesis
and antioxidant metabolic reactions to lower the oxida-
tive condition in tissues (liver and muscle).
T1AM treatment improves nitrogen and amino acid
metabolism in muscles from GC-mice by downregulating
SIRT5, an important regulator of nitrogen metabolism,
BCAT2 expression, and BCAA metabolite levels (Fig. 4F).
We previously showed that nighttime nitrogen excretion in
urine was positively correlated with circulating testosterone
levels in PCOS women (Whigham et al. 2013). Previous
studies showed that increased levels of BCAA and
decreased level of Gly improve insulin sensitivity (Muoio
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et al. 2002). BCAA levels are increased while Gly is
decreased in muscles from T1AM-treated GC-mice, indi-
cating that insulin sensitivity is improved in nondiabetic
GC-mice.
In contrast to other tissues, T1AM has opposing effects
on cholesterol metabolism leading to steroidogenesis in
ovaries of GC-mice (Fig. 5D). In the normal ovary, andro-
gens are synthesized from cholesterol in the theca cells. The
ovary is also the primary source of increased circulating
androgens (Franks 1995; Legro et al. 1998; Ehrmann 2005).
In the ovary from a subset of PCOS women (25–60%)
(Moran et al. 1999; Kumar et al. 2005), increased adrenal
steroidogenesis contributes to increased circulating andro-
gen and impaired insulin signaling as phenotypic hallmarks
of (Handwerger et al 2008), making it difficult to pinpoint
which upstream gene networks and metabolic signaling
pathways participate in the manifestation of these PCOS
phenotypes. However, treatment of PCOS women with
insulin-sensitizing drugs (e.g., metformin, pioglitazone)
results in a reversal of ovarian phenotype (Legro 2001). In
our study, T1AM lowers fasting circulating glucose levels in
GC-mice (Table 1) but with trends in increasing insulin
level, which suggest an upstream glucose–lipid signaling
regulatory mechanism. The effect of subchronic application
of low pharmacological dose of T1AM on cholesterol
that leads to estrogenic hormone synthesis in ovaries of
GC-mice is the opposite of other metabolic tissues. This
observation may be due to an increased supply of choles-
terol and FAs as precursors for estrogenic hormone synthe-
sis, nevertheless it points to fundamental dysregulation of
hormonal pathways in the ovary of GC-mice, which
requires further examination.
Leptin and adiponectin are adipose tissue-derived hor-
mone peptides that play important regulatory roles in
energy, glucose homeostasis, and lipid metabolism
(Robinson et al. 2011). Despite decreased body weight
and improved lipid profile, the circulating levels of hor-
mones were not significantly reduced. This may be due to
our lower animal number derived from diverse outbred
CD-1 genetic background or the shorter length of treat-
ment period. In particular, in the anti-obesity hormone,
leptin level is not only positively correlated with body fat
content, but also negatively correlated with lower energy
intake and energy stores (Boden et al. 1996). Level of lep-
tin in normal subjects is correlated with a number of
endocrine hormones such as insulin, glucocorticoid, and
testosterone (Janeckova 2001). However, the increased
level of leptin after T1AM treatment may be due to the
preexisting pathophysiology in our model of prenatal
exposure to a glucocorticoid.
At present, direct intracellular mechanism of T1AM
action is not known; multiple lines of research including this
study support the hypothesis that T1AM is a multitargeted
ligand. Although T1AM is structurally similar to TH hor-
mone, functionally T1AM’s action is through a different
mechanism. In TH nuclear receptor-binding assays and TR
reporter gene activation assays, T1AM shows neither affinity
for TRa or TRb, nor an ability to stimulate or inhibit
nuclear TR-mediated transactivation (Scanlan et al. 2004).
At present, the only known molecular targets of T1AM are
trace amine receptor (TAAR1), a2A adrenergic receptor,
DAT, and NET VMAT2 proteins (Snead et al. 2007). While
T1AM inhibits monoamine transport, it is shown to be a
potent agonist of the G protein-coupled trace amine recep-
tor TAAR1 (Scanlan et al. 2004). The presence of TAAR1
receptor in the brain may be in part responsible for the
metabolic responses, such as changes in fuel utilization, food
intake, and behavioral activity. At physiological level, T1AM
is considered an endogenous hormone that when adminis-
tered in rodents at high dose (50 mg/kg/day) depresses
metabolism by a rapid interruption of carbohydrate fueling
accompanied by a compensatory rise in lipid utilization
(Braulke et al. 2008), and shift in metabolism from carbohy-
drate to lipid breakdown (Haviland et al. 2012). T1AM
inhibits insulin secretion and induces hyperglycemia in mice
via Gi signaling through the a2A receptor while its activa-
tion of the Gs-coupled TAAR1 stimulates insulin secretion
and results in hypoglycemia when the a2A receptor is
blocked or absent (Ianculescu and Scanlan 2010). The tar-
geted metabolomics research opens up a new avenue for
future research to examine the new intracellular signaling
mechanism of T1AM action through regulatory and/or sig-
naling (e.g., sirtuin-mediated) pathways.
In summary, our results reveal a new paradigm about
the downstream effect of T1AM treatment in GC-mice
through gene signaling that regulates lipid and cholesterol
metabolism differentially (Fig. 5). This mechanism of
action is distinct from T1AM’s acute rapid onset of meta-
bolic effects mediated by cell surface G protein-coupled
receptors as previously proposed by Scanlan et al. (2004).
Taken together, these findings provide a basis for under-
standing T1AM’s increased lipolytic and decreased lipo-
genic metabolic effects. Thus, T1AM may serve as a
promising endogenous supplement in the treatment of
dysfunctional lipid metabolism such as fatty liver disease,
obesity, and PCOS. This study could open up a new ave-
nue for future research to understand alternative modes
of hormone metabolic pathway-mediated regulation and
develop new approaches for essential therapeutic targets
in order to manage complex metabolic diseases and
improve health outcomes in women with PCOS.
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